- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: July 2016
- Public Summary Document (PSD) July 2016 PBAC Meeting - PDF
- Public Summary Document (PSD) July 2016 PBAC Meeting - Word
Omalizumab – July 2016
Omalizumab: 75 mg/0.5 mL injection, 1 × 0.5 mL syringe, 150 mg/mL injection, 1 × 1 mL syringe, Xolair®
Last updated
28 October 2016